Rare but serious gastrointestinal complications have been reported in post-marketing surveillance, including: Acute pancreatitis : If suspected, the GLP-1 agonist should be stopped immediately and not restarted if pancreatitis is confirmed Severe gastroparesis : Rare post-marketing reports of severe delayed gastric emptying Intestinal obstruction : Very rare cases reported in post-marketing surveillance Patients should be advised to seek urgent medical help via NHS 111, A&E or 999 as appropriate if they experience severe or persistent abdominal pain, persistent vomiting, abdominal distension, inability to pass stool or gas, or bloody diarrhoea whilst taking GLP-1 agonists
Histopathological analysis confirms that tumor cell accumulation is localized within the dissolving hydrogel, while adjacent neural parenchyma remains unperturbed
STEP 1 showed 14.9% total weight loss with reduction in both visceral and subcutaneous fat
If you are asking Is Tirzepatide the Same as Mounjaro, this post lays out the facts about brand name versus generic, how the drug works through GIP and GLP 1 pathways, what clinical trials show for weight loss, and the common side effects so you can compare efficacy, dosing and safety
They can affect the release and activity of neurotransmitters such as dopamine and serotonin, which play a crucial role in emotional well-being, Arillotta added